Table 3.

Risk of Measles Immunoglobulin G Seroconversion After Initiation of Highly Active Antiretroviral Therapy Before and During the Measles Outbreak and After Measles Revaccination Among HIV-Infected Seronegative Children at Study Enrollment

Characteristic	Hazard Ratio (95% CI)
Months since HAART initiation
3	Reference
6	1.08 (.43–2.71)
9	0.13 (.02–.98)
12	0.96 (.35–2.69)
15	0.86 (.27–2.69)
18	0.99 (.25–3.89)
During outbreak, prior to revaccination	2.48 (.86–7.11)
After revaccination	9.85 (3.78–25.7)
6-mo increase in baseline age	1.08 (.90–1.29)
5% change in baseline CD4+ T cells	1.09 (.83–1.43)

Abbreviations: CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.